샘플 요청 목록

 카트 문의
시장보고서
상품코드
1953503

최종당화산물 저해제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 약제별, 적응증별, 유통 채널별, 지역별, 경쟁(2021-2031년)

Advanced Glycation End Products Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug, By Indication, By Distribution Channel, By Region & Competition, 2021-2031F
발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 180 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 최종당화산물(AGE) 저해제 시장은 2025년 4억 6,000만 달러에서 2031년까지 6억 5,000만 달러로 확대하며, CAGR 5.93%로 추이할 것으로 예측됩니다.

이들 억제제는 만성질환에서 조직 손상의 원인이 되는 당과 단백질의 비효소적 가교반응을 억제하도록 설계된 전문 치료제입니다. 시장 성장은 주로 당뇨병성 신증과 같은 노화 관련 질환과 대사 장애의 발생률 증가에 의해 주도되고 있으며, 이에 대한 효과적인 관리가 필요합니다. 국제당뇨병연맹(IDF)에 따르면 2024년 기준 전 세계 20세에서 79세 사이의 성인 약 5억 8,900만 명이 당뇨병을 앓고 있으며, 당화증으로 인한 합병증을 줄이기 위한 중재책의 중요성이 부각되고 있습니다.

시장 개요
예측 기간 2027-2031년
시장 규모 : 2025년 4억 6,000만 달러
시장 규모 : 2031년 6억 5,000만 달러
CAGR : 2026-2031년 5.93%
가장 빠르게 성장하는 부문 변성 질환
최대 시장 북미

그러나 이 치료법에 대한 임상 적용에 있으며, 업계는 심각한 문제에 직면해 있습니다. 그동안 많은 유망한 후보물질들이 후기 임상시험에서 충분한 안전성과 유효성을 입증하지 못해 엄격한 규제 감시를 받아왔습니다. 이러한 의약품 개발의 높은 실패율은 막대한 재정적 리스크를 초래하고 주요 장벽으로 작용하여 이 치료 분야에서 새로운 억제제의 신속한 상용화와 광범위한 보급을 지연시키고 있습니다.

시장 성장 촉진요인

당뇨병 및 관련 미세혈관 합병증 증가는 세계 당화혈색소(AGE) 억제제 시장의 주요 촉진요인으로 작용하고 있습니다. 고혈당은 단백질의 비효소적 당화를 촉진하고 AGE의 축적을 유발하여 당뇨병성 신증과 같은 심각한 질환의 발병에 핵심적인 역할을 합니다. 2024년 11월 The Lancet의 분석에 따르면 전 세계 성인 당뇨병 환자 수는 8억 명을 돌파하여 1990년 대비 4배 증가하여 장기 손상을 예방하는 억제제의 임상적 필요성이 시급히 대두되고 있습니다. 또한 미국 질병예방통제센터(CDC)는 2024년 기준 미국 성인의 3,550만 명이 만성 신장 질환을 앓고 있는 것으로 추정하고 있으며, 이 질환은 종종 AGE로 인해 악화되므로 수요를 더욱 촉진하고 있습니다.

시장 성장은 빠르게 증가하는 세계 고령자 인구에 의해 더욱 촉진되고 있습니다. 노인은 노화 관련 질병에 걸리기 쉽고, AGE 축적은 노화 과정을 나타내는 중요한 생물학적 지표가 됩니다. 조직이 노화됨에 따라 당화 단백질을 대체하는 능력이 저하되어 혈관의 경화 및 탄력성 감소를 유발합니다. 이를 위해서는 약리학적인 개입이 필요합니다. 2024년 7월 발표된 유엔의 '세계 인구 예측 2024' 보고서에 따르면 세계 출생시 평균 수명이 73.3세에 달하고, 당화 장애가 나타날 수 있는 기간이 실질적으로 연장되었습니다. 이에 따라 제약사들은 장수화에 따른 만성질환 관리 수요에 대응하기 위해 R&D 파이프라인의 조정에 박차를 가하고 있습니다.

시장이 해결해야 할 과제

세계 당화혈색소(AGE) 억제제 시장의 성장을 가로막는 주요 장벽은 임상시험에서 높은 탈락률입니다. 이는 재무적 불확실성을 야기하고 상품화 지연을 초래합니다. 대사성 질환 및 노화 관련 질환에 대한 신약 개발은 특히 복잡하며, 후기 임상시험에서 유효성 평가변수를 달성하지 못하는 후보물질이 빈번하게 발생하고 있습니다. 이러한 예측 불가능성으로 인해 제약사들은 AGE 억제제 연구에 많은 투자를 주저하고 있으며, 개발 비용 상승에 대한 투자수익률을 정당화하기 어려운 경우가 많아 파이프라인이 정체되고 시장 확대가 제한되고 있습니다.

이 문제는 신약개발의 불안정성을 보여주는 최근 업계 통계에서 더욱 부각되고 있습니다. 생명공학혁신기구(BIO)의 2024년 데이터에 따르면 임상 개발 단계에 있는 신약의 전체 성공률은 6.7%에 불과한 것으로 나타났습니다. 이러한 낮은 성공 확률은 AGE 억제와 같은 새로운 메커니즘을 추구하는 개발자들이 직면한 엄청난 위험을 강조합니다. 이해관계자들이 해당 자산군의 실패 가능성이 높다고 인식하면, 자본 유입이 감소하고 해당 분야의 혁신 속도가 크게 둔화될 수 있습니다.

시장 동향

AGE 억제제가 안티에이징 스킨케어와 화장품에 접목되면서 시장은 근본적인 변화를 겪고 있습니다. 이들은 임상용 당뇨병 치료제에서 수요가 높은 소비자용 미용제품으로 전환되고 있습니다. 화장품 제조업체들은 피부의 황변과 탄력 상실의 원인이 되는 콜라겐 섬유의 가교 반응을 막기 위해 메이라드 반응을 표적으로 하는 외용제제 개발을 적극적으로 추진하고 있습니다. 예를 들어 L'Oreal은 2025년 2월 발표한 '2024 회계연도 결산 보고서'에서 R&D 및 혁신에 13억 유로 이상을 투자했다고 보고하고, 항당화 기술을 포함한 생물학적 메커니즘 개발에 많은 자금을 투자하여 소비자가 원하는 피부 젊음 유지 솔루션에 대응하는 자세를 강조했습니다. 강조했습니다.

동시에, AGE(당화 최종산물)를 타겟으로 한 기능성 식품과 뉴트리슈티컬의 등장은 식단을 통한 예방적 대사 관리로의 전략적 전환을 보여줍니다. 소비자들이 식습관을 장수의 주요 수단으로 인식하는 가운데, 제조업체들은 만성질환 발병 전 전신 당화 스트레스를 줄이기 위해 폴리페놀, 플라보노이드와 같은 천연 AGE 억제제를 제품에 강화하여 배합하고 있습니다. 이러한 추세는 '음식은 약이다'라는 보다 광범위한 움직임에 의해 더욱 가속화되고 있습니다. 미국 식품기술자협회(IFT)의 2025년 4월 보고서에 따르면 미국내 건강식품 및 음료의 소매 매출은 2024년 3,200억 달러에 달할 것으로 예상되며, 이는 대사 노화 과정에 대응하도록 설계된 기능성 제제의 거대한 시장 잠재력을 지원합니다.

자주 묻는 질문

  • 세계의 최종당화산물(AGE) 저해제 시장 규모는 어떻게 변할 것으로 예상되나요?
  • AGE 저해제 시장의 주요 성장 촉진 요인은 무엇인가요?
  • AGE 저해제 시장에서 가장 빠르게 성장하는 부문은 무엇인가요?
  • AGE 저해제 시장의 최대 시장은 어디인가요?
  • AGE 저해제 시장의 성장에 영향을 미치는 주요 과제는 무엇인가요?
  • AGE 저해제 시장의 최근 동향은 무엇인가요?
  • AGE 저해제 시장에서 주요 기업은 어디인가요?

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 최종당화산물(AGE) 저해제 시장 전망

제6장 북미의 최종당화산물(AGE) 저해제 시장의 전망

제7장 유럽의 최종당화산물(AGE) 저해제 시장의 전망

제8장 아시아태평양의 최종당화산물(AGE) 저해제 시장의 전망

제9장 중동 및 아프리카의 최종당화산물(AGE) 저해제 시장의 전망

제10장 남미의 최종당화산물(AGE) 저해제 시장의 전망

제11장 시장 역학

제12장 시장 동향과 발전

제13장 세계의 최종당화산물(AGE) 저해제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

제15장 경쟁 구도

제16장 전략적 제안

제17장 조사회사 소개·면책사항

KSA 26.03.19

The Global Advanced Glycation End-Products (AGE) Inhibitors Market is projected to expand from USD 0.46 Billion in 2025 to USD 0.65 Billion by 2031, reflecting a compound annual growth rate of 5.93%. These inhibitors are specialized therapeutic agents designed to obstruct the non-enzymatic crosslinking of sugars and proteins, a process that contributes to tissue damage in chronic diseases. The market's growth is largely driven by the rising incidence of aging-related conditions and metabolic disorders, such as diabetic nephropathy, which necessitate effective management. According to the International Diabetes Federation, approximately 589 million adults aged 20 to 79 were living with diabetes globally in 2024, highlighting the critical need for interventions that reduce complications caused by glycation.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 0.46 Billion
Market Size 2031USD 0.65 Billion
CAGR 2026-20315.93%
Fastest Growing SegmentDegenerative Diseases
Largest MarketNorth America

However, the industry faces significant hurdles regarding the clinical translation of these therapeutics. Historically, many potential candidates have failed to demonstrate adequate safety or efficacy during late-stage human trials, resulting in strict regulatory oversight. This high attrition rate in drug development creates substantial financial risk and serves as a primary obstacle, delaying the rapid commercialization and widespread availability of novel inhibitors within this therapeutic category.

Market Driver

The increasing prevalence of diabetes and its associated microvascular complications acts as a primary catalyst for the Global Advanced Glycation End-Products (AGE) Inhibitors Market. High blood sugar levels accelerate the non-enzymatic glycation of proteins, causing the accumulation of AGEs which are central to the development of severe conditions like diabetic nephropathy. A November 2024 analysis by The Lancet revealed that the global number of adults with diabetes has surpassed 800 million, a fourfold increase since 1990, creating an urgent clinical necessity for inhibitors to prevent organ damage. Additionally, the Centers for Disease Control and Prevention estimated in 2024 that 35.5 million adults in the United States suffer from chronic kidney disease, a condition often exacerbated by AGEs, further fueling demand.

Market growth is further propelled by the rapidly expanding global geriatric population, which is highly susceptible to age-related pathologies where AGE accumulation serves as a key biological marker of senescence. As tissues age, their ability to replace glycated proteins diminishes, leading to vascular stiffening and reduced elasticity that requires pharmacological intervention. According to the United Nations' "World Population Prospects 2024" report from July 2024, global life expectancy at birth reached 73.3 years, effectively extending the period during which glycation disorders can manifest. Consequently, pharmaceutical companies are increasingly adjusting their research and development pipelines to meet the chronic management needs associated with longer lifespans.

Market Challenge

A major obstacle hampering the growth of the Global Advanced Glycation End-Products (AGE) Inhibitors Market is the high rate of attrition in clinical trials, which generates financial uncertainty and delays commercialization. The development of new therapeutics for metabolic and aging-related diseases is notably complex, frequently resulting in candidates failing to meet efficacy endpoints in late-stage studies. This unpredictability discourages pharmaceutical firms from investing heavily in AGE inhibitor research, as the potential return on investment is often difficult to justify against the soaring costs of development, thereby stagnating the pipeline and limiting market expansion.

This challenge is underscored by recent industry statistics that reveal the precarious nature of drug discovery. Data from the Biotechnology Innovation Organization in 2024 indicated that the overall clinical development success rate for investigational drugs fell to just 6.7%. Such a low probability of success highlights the immense risks developers face when pursuing novel mechanisms like AGE inhibition. When stakeholders perceive an asset class as having a high potential for failure, capital inflows decrease, significantly slowing the pace of innovation within the sector.

Market Trends

The integration of AGE inhibitors into anti-aging skincare and cosmeceuticals is fundamentally transforming the market by shifting these agents from clinical diabetic treatments to high-demand consumer beauty products. Cosmetic manufacturers are aggressively developing topical formulations that target the Maillard reaction to prevent the cross-linking of collagen fibers, which leads to skin yellowing and loss of elasticity. For instance, L'Oreal reported in its "2024 Annual Results" in February 2025 that it invested over €1.3 billion in Research & Innovation, emphasizing the significant financial resources now dedicated to developing biological mechanisms, including anti-glycation technologies, to meet consumer demand for skin longevity solutions.

Simultaneously, the rise of AGE-targeting functional foods and nutraceuticals represents a strategic pivot toward preventive metabolic management through diet. As consumers increasingly view diet as a primary tool for longevity, manufacturers are fortifying products with natural AGE inhibitors, such as polyphenols and flavonoids, to mitigate systemic glycation stress before chronic diseases appear. This trend is amplified by the broader "food as medicine" movement; according to the Institute of Food Technologists' April 2025 report, retail sales of healthy food and beverages in the United States reached $320 billion in 2024, underscoring the vast market potential for functional formulations designed to counteract metabolic aging processes.

Key Market Players

  • DSM
  • BASF
  • Lonza
  • Heel
  • Clinicians & Small Biotechs
  • Sanofi
  • Pfizer
  • GSK
  • TSI Group
  • Academic Spinouts

Report Scope

In this report, the Global Advanced Glycation End-Products (AGE) Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Advanced Glycation End-Products (AGE) Inhibitors Market, By Drug

  • Carnosine
  • Pyridoxine
  • Agmatine
  • Benfotiamine
  • Alpha Lipoic Acid
  • Others

Advanced Glycation End-Products (AGE) Inhibitors Market, By Indication

  • Metabolic Diseases
  • Cardiovascular Diseases
  • Degenerative Diseases
  • Others

Advanced Glycation End-Products (AGE) Inhibitors Market, By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

Advanced Glycation End-Products (AGE) Inhibitors Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Advanced Glycation End-Products (AGE) Inhibitors Market.

Available Customizations:

Global Advanced Glycation End-Products (AGE) Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Advanced Glycation End-Products (AGE) Inhibitors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug (Carnosine, Pyridoxine, Agmatine, Benfotiamine, Alpha Lipoic Acid, Others)
    • 5.2.2. By Indication (Metabolic Diseases, Cardiovascular Diseases, Degenerative Diseases, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Advanced Glycation End-Products (AGE) Inhibitors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug
    • 6.2.2. By Indication
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Distribution Channel

7. Europe Advanced Glycation End-Products (AGE) Inhibitors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug
    • 7.2.2. By Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Advanced Glycation End-Products (AGE) Inhibitors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug
    • 8.2.2. By Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Advanced Glycation End-Products (AGE) Inhibitors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug
    • 9.2.2. By Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Distribution Channel

10. South America Advanced Glycation End-Products (AGE) Inhibitors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug
    • 10.2.2. By Indication
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Advanced Glycation End-Products (AGE) Inhibitors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Advanced Glycation End-Products (AGE) Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. DSM
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. BASF
  • 15.3. Lonza
  • 15.4. Heel
  • 15.5. Clinicians & Small Biotechs
  • 15.6. Sanofi
  • 15.7. Pfizer
  • 15.8. GSK
  • 15.9. TSI Group
  • 15.10. Academic Spinouts

16. Strategic Recommendations

17. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제